| High-dose rifapentine with moxifloxacin for pulmonary tuberculosis A Jindani, TS Harrison, AJ Nunn, PPJ Phillips, GJ Churchyard, ... New England Journal of Medicine 371 (17), 1599-1608, 2014 | 494 | 2014 |
| CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an … M Dhoro, S Zvada, B Ngara, C Nhachi, G Kadzirange, P Chonzi, ... BMC Pharmacology and Toxicology 16, 1-10, 2015 | 88 | 2015 |
| Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses SP Zvada, P Denti, PR Donald, HS Schaaf, S Thee, JA Seddon, HI Seifart, ... Journal of Antimicrobial Chemotherapy 69 (5), 1339-1349, 2014 | 76 | 2014 |
| Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients SP Zvada, P Denti, FA Sirgel, E Chigutsa, M Hatherill, S Charalambous, ... Antimicrobial agents and chemotherapy 58 (1), 503-510, 2014 | 56 | 2014 |
| Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers SP Zvada, JS Van Der Walt, PJ Smith, PB Fourie, G Roscigno, ... Antimicrobial agents and chemotherapy 54 (8), 3390-3394, 2010 | 45 | 2010 |
| Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine SP Zvada, P Denti, H Geldenhuys, S Meredith, D van As, M Hatherill, ... Antimicrobial agents and chemotherapy 56 (8), 4471-4473, 2012 | 39 | 2012 |
| In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug … RS Thelingwani, SP Zvada, H Dolgos, ALB Ungell, CM Masimirembwa Drug metabolism and disposition 37 (6), 1286-1294, 2009 | 36 | 2009 |
| Pharmacometrics: opportunity for reducing disease burden in the developing world: the case of Africa G Pillai, G Davies, P Denti, JL Steimer, H McIlleron, S Zvada, E Chigutsa, ... CPT: pharmacometrics & systems pharmacology 2 (8), 1-4, 2013 | 23 | 2013 |
| A population pharmacokinetic analysis shows that arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of rifapentine J Francis, SP Zvada, P Denti, M Hatherill, S Charalambous, S Mungofa, ... Antimicrobial agents and chemotherapy 63 (4), 10.1128/aac. 01964-18, 2019 | 17 | 2019 |
| Does hepatic impairment affect the exposure of monoclonal antibodies? Q Sun, S Seo, S Zvada, C Liu, K Reynolds Clinical Pharmacology & Therapeutics 107 (5), 1256-1262, 2020 | 15 | 2020 |
| A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents B Ngara, S Zvada, TD Chawana, B Stray-Pedersen, CFB Nhachi, ... BMC Pharmacology and Toxicology 21, 1-9, 2020 | 4 | 2020 |
| Population pharmacokinetics of rifampicin in childhood tuberculosis and the need for dose adjustment SP Zvada, USH Simonsson, P Denti, PR Donald, HS Schaaf, PJ Smith, ... Abstract book; 3rd International Workshop on Clinical Pharmacology of …, 2010 | 2 | 2010 |
| An experimental pharmacokinetic computer program to predict potential drug-drug interactions SP Zvada, TE Chagwedera, R Chigwanda, CM Masimirembwa The Open Drug Metabolism Journal 3 (1), 2009 | 2 | 2009 |
| Pharmacokinetic-pharmacodynamic modelling of atazanavir in hair among adolescents on antiretroviral treatment in Zimbabwe B Ngara, S Zvada, TD Chawana, CFB Nhachi, S Rusakaniko BMC Pharmacology and Toxicology 22 (1), 29, 2021 | | 2021 |
| Arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection 3 affect the exposure of Rifapentine: a population pharmacokinetics analysis. 4 J Francis, SP Zvada, P Denti, M Hatherill, S Charalambous, S Mungofa, ... | | 2019 |
| IDENTIFICATION OF DOSE AND DURATION OF PTH1-34 ADMINISTRATION SUITABLE FOR USE IN PROOF OF CONCEPT STUDIES USING MODELING AND SIMULATION S Zvada, B Thomas, G Pillai, C Zhang, P Denti BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 115, 264-265, 2014 | | 2014 |
| Optimization of 1st-line antituberculosis dosing regimens using a population pharmacokinetic approach: food effects, drug combinations and pharmacological effects SP Zvada | | 2014 |
| 2024 Rome, Italy B Francis, SP Zvada, P Denti, M Hatherill, S Charalambous, S Mungofa, ... | | |
| Population Approach Group Europe Population Approach Group Europe T Dorlo | | |
| Population Approach Group Europe Population Approach Group Europe R Keizer | | |
